Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Phase 2
Active, not recruiting
NCT02912572
| Condition | Metastatic Endometrial Cancer |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Dana-Farber Cancer Institute |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 106 participants |
|---|
| Interventions | Avelumab, Talazoparib, Axitinib |
|---|
| Start date | Nov 14, 2016 |
|---|
| Completion date | Nov 15, 2023 |
|---|
| Results posted | Jul 5, 2024 |
|---|
Summary
This research study is evaluating a drug called Avelumab alone and in combination with Talazoparib or Axitinib as a possible treatment for recurrent or metastatic endometrial cancer.
Objective Response Rate
Up to 39 months · Participants
| MSI-H/POLE-Mutated Avelumab Arm | 4 Participants |
|---|
| MSS Avelumab Arm | 1 Participants |
|---|
| MSS Avelumab/Talazoparib Combination Arm | 4 Participants |
|---|
| MSS Avelumab/Axitinib Combination Arm | 9 Participants |
|---|
Progression-Free Survival at 6 Months
6 months · Participants
| MSI-H/POLE-Mutated Avelumab Arm | 6 Participants |
|---|
| MSS Avelumab Arm | 1 Participants |
|---|
| MSS Avelumab/Talazoparib Combination Arm | 8 Participants |
|---|
| MSS Avelumab/Axitinib Combination Arm | 14 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.